trending Market Intelligence /marketintelligence/en/news-insights/trending/1KOs0Fwt46Csov5_3Eix2Q2 content esgSubNav
In This List

Provention Bio prices $40M stock offering, $20M private placement with Amgen

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Provention Bio prices $40M stock offering, $20M private placement with Amgen

Provention Bio Inc. priced its public offering of 5 million common shares at $8 apiece.

The Oldwick, N.J.-based biopharmaceutical company also granted underwriters a 30-day option to buy up to an additional 750,000 shares under the offer.

Provention Bio expects gross proceeds of $40 million from the offering.

The offering is expected to close on or about Sept. 23, subject to customary closing conditions.

In addition, the company is selling 2.5 million common shares at $8 apiece in a private placement to Thousand Oaks, Calif.-based Amgen Inc. Provention Bio expects $20 million in gross proceeds from the placement.

Provention Bio intends to use net proceeds from the public offering and private placement for general corporate purposes, including the advancement of product candidates.

SVB Leerink and Cantor Fitzgerald & Co. are acting as joint book-running managers for the public offering, while H.C. Wainwright & Co. is acting as lead manager for the same offer.